Research programme: pain therapeutics - TransMolecular
Latest Information Update: 27 Nov 2007
At a glance
- Originator TransMolecular
- Mechanism of Action Sodium channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 11 Jul 2003 Early research in Pain in USA (unspecified route)
- 11 Jul 2003 Transmolecular is seeking partners to develop new chemical entries for the treatment of pain in the US (http://www.transmolecular.com)